1Janni W,Hepp P. Adjuvant aromatase inhibitor therapy: outcomes and safety [J]. Cancer Treat Rev, 2010,36(3): 249-261.
2Jones SE, Hasenburg A, Rae D, et al. Results of the first planned analysis of the TEAM (tamoxifen exemestane ad- juvant muhinational) prospective randomized phase m trial in hormone sensitive postmenopausal early breast cancer [C]. San Antonio TX: 31st Annual San Antonio Breast Cancer Symposium, 2008.
3Forbes JF, Cuzick J, Buzdar A, et al. Effect of anastro- zole and tamoxifen as adjuvant treatment for early-stage breast cancer: lO0-month analysis of the ATAC trial[J]. Lancet Oncol, 2008,9( 1 ): 45-53.
4Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with ear- ly breast cancer: first results of the ATAC randomised trial [J]. Lancet, 2002, 359(9324): 2131-2139.
5Thurlimann B, Keshaviah A, Coates AS, et al. A com- parison of letrozole and tamoxifen in postmenopausal women with early breast cancer [J]. N Engl J Med, 2005,353 (26): 2747-2757.
6Joerger M, Thurlimann B. Update of the BIG 1-98 trial: where do we stand?[J]. Breast, 2009, 18(Suppl 3): s78-s82.
7Giobbie-Hurder A, Price KN,Gelber RD. Design, con- duct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-Ill study compar- ing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer[J]. Clin Trials, 2009, 6(3): 272-287.
8Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log- rank tests[J]. Biometrics, 2000, 56(3): 779-788.
9van de Velde C J, Verma S, van Nes JG, et al. Switching from tamoxifen to aromatase inhibitors for adjuvant en- docrine therapy in postmenopausal patients with early breast cancer[J]. Cancer Treat Rev, 2010, 36(1): 54-62.
10Jakesz R, Jonat W, Gnant M, et al. Switching of post- menopausal women with endocrine-responsive early breastcancer to anastrozole after 2 years" adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial[J]. Lancet, 2005, 366(9484): 455-462.
7Zwiefel K, Janni W. Current standards in the treatment of breast cancer[J]. Med Manatsschr Pharm,2011,34(8) :280 -288.
8Obiorah I, Jordan VC. Matufitas. Progress in endocrine approaches to the treatment and prevention of breast cancer [ J ]. Maturitas, 2011,70(4) :315 -321.
9Janni W, Hepp P. Adjuvant aromatase inhibitor therapy:outcomes and safety [J]. Cancer Treat Rev, 2010,36(3) :249 -261.
10Osborne CK. Adjuvant endocrine therapy. [M].Harris,Lippman, Morrow, et al. Diseases of the breast. 3rd Ed.USA. Lippincott: Williams & Wilkins,2004:865-891.
